Pertuzumab for Breast Cancer: 42 Real Stories

42 stories match breast cancer and pertuzumab. 31 of them mention surgery.

Cancer Stories

Pilar, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Pilar's Patient Story

Patient Info: Pilar, Female, 40s | Stage IV

Biomarkers: Hormone receptor-positive; HER2-positive

Pilar was living with metastatic hormone receptor-positive, HER2-positive breast cancer, continuing systemic treatment with Zoladex, aromatase inhibitors, trastuzumab, and pertuzumab, and managing side effects with rehabilitation support.

MatchTrial Historias Reales
OutcomeLiving With Cancer
Genevieve, who was diagnosed with Breast CancerBreast Cancer

Breast Cancer: Genevieve's Survivor Story

Patient Info: Genevieve, Female, 40s

Biomarkers: 1987 tumor not hormone-receptive; 2017 tumor hormone-receptive. 2022 full marker panel not stated.

After breast cancer episodes beginning in 1987, another tumor in 2017, and cancer found again in 2022, PET scans every 3-4 months were clear and she described herself as in remission again as of May 2025.

breastcancer.org
OutcomeCancer-Free / NED
Jennifer, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Jennifer's Patient Story

Patient Info: Jennifer Feinberg, Female, 40s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: brain

8+ years after her initial breast cancer diagnosis, she was living with metastatic HER2-positive breast cancer with brain metastases and receiving trastuzumab as her tenth line of treatment.

Dana-Farber
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

HER2-positive breast cancer complicated by severe anemia during chemotherapy

Patient Info: Anonymized, female, 40s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-positive; germline BRCA1 likely pathogenic mutation

At 4.5-year follow-up, she remained free of breast-cancer recurrence and had no recurrence of the severe treatment-related anemia.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage II Breast CancerBreast Cancer

HER2-Positive Breast Cancer Treatment Followed by Multiple Myeloma

Patient Info: Anonymized, female, 50s | Stage II

Biomarkers: ER-negative; PR-negative; HER2 3+; Ki-67 70%

Postoperative imaging showed no breast cancer recurrence or distant metastasis, and the breast cancer was described as stable when a separate multiple myeloma diagnosis was made.

PubMed Central
OutcomeCancer-Free / NED
Alison, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HR-Positive Breast Cancer: Alison's Survivor Story

Patient Info: Alison, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Cervical/neck lymph nodes

Alison reported complete remission since August 2017 while continuing intermittent maintenance chemotherapy, most recently 1 month of treatment followed by 2 months off.

The Patient Story
OutcomeLiving With Cancer / Remission
Renee, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage IV HER2-Positive Invasive Ductal Carcinoma: Renee's Patient Story

Patient Info: Renee N., Female | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Brain

As of June 2026, Renee’s public story described living with metastatic HER2-positive breast cancer as a chronic illness, after brain radiation and while on Kadcyla every 3 weeks with stable scans reported in December 2019 and early March 2020.

The Patient Story
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

HER2-positive breast cancer: brain recurrence, T-DXd liver injury, and later progression

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HER2-positive; hormone receptor-negative; grade 3 infiltrative breast carcinoma

Metastatic Site: brain; thoracic lymph nodes

As of October 2025, the patient had developed brain and thoracic nodal recurrence after HER2-directed treatment, experienced T-DXd-associated liver injury, progressed after later paclitaxel/trastuzumab, and died at home in December 2024 under palliative care.

PubMed Central
OutcomeIn Memory
Paul, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Paul's Patient Story

Patient Info: Paul Forgette, Male, 60s | Stage IV

Biomarkers: HER2-positive; triple-positive breast cancer; CHEK2 mutation

Metastatic Site: Bones; lymph nodes

By October 2025, 9 months after starting Enhertu, Paul’s Stage IV HER2-positive male breast cancer was described as dormant, not cured, with continued City of Hope care and integrative support.

City of Hope
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

ER/PR/HER2-positive breast cancer: gallbladder, liver, lung, pleural, and bone metastases after incomplete adjuvant therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Triple-positive breast cancer. Gallbladder metastasis kept ER/PR/HER2 positivity and Ki-67 >40%; markers supported breast origin.

Metastatic Site: gallbladder, liver, lung/pleura, bone

The patient died 3 years and 10 months after lumpectomy after metastatic ER/PR/HER2-positive breast cancer involved the gallbladder, liver, lungs/pleura, and bones following incomplete adjuvant therapy and loss to surveillance.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage III Breast CancerBreast Cancer

HER2-positive node-positive breast cancer: mastectomy and adjuvant TCbHP

Patient Info: Anonymized, Female, Under 40 | Stage III

Biomarkers: HER2-positive breast cancer with ER/PR positivity, PD-L1 CPS 25

Adjuvant TCbHP was initiated after surgery, the first cycle was tolerated with supportive care, and regular monitoring was ongoing without evidence of distant recurrence or metastasis reported.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

HER2-positive breast cancer with brain, skin, and lymph-node metastases responding to dual-targeted therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: HER2-positive breast cancer. Initial tumor was ER/PR negative with Ki-67 30%; skin metastasis had Ki-67 70%.

Metastatic Site: brain, left cervical lymph nodes, skin of left chest…

After 1 cycle of inetetamab trastuzumab, pyrotinib, and capecitabine, skin metastases regressed, CEA and CA125 decreased, brain lesions shrank, and the largest lesion decreased by about 46%, meeting partial response; disease remained stable as of September 2024.

PubMed Central
OutcomeResponding Well
Kathleen, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Kathleen's Patient Story

Patient Info: Kathleen McEvoy-Schufreider, female, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver, bones

Kathleen continued long-term treatment for metastatic breast cancer, including infusions every 3 weeks after resuming the PATINA regimen outside the trial.

Dana-Farber
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

HER2-positive breast cancer with brain metastases: responding well to T-DXd

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive / HER2 IHC 3+

Metastatic Site: brain (left cerebellum, left frontal lobe, medulla)

After 14 months and 19 doses of T-DXd, brain metastases remained controlled with no symptomatic or radiological relapse and no severe T-DXd-related adverse events.

PubMed Central
OutcomeResponding Well
Stephani, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Stephani's Survivor Story

Patient Info: Stephani St. Cyr, Female | Stage IV

Biomarkers: HER2-targeted treatments reported; no inherited cancer gene mutation found.

Metastatic Site: Bone; liver; brain

As of March 2025, Stephani had Stage IV metastatic breast cancer involving bone, liver, and brain, had no evidence of disease since July 2021, and continued HER2-targeted/systemic therapy.

Living Beyond Breast Cancer
OutcomeCancer-Free / NED
Anne, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Anne's Patient Story

Patient Info: Anne Keane, 40s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: bones, liver

Anne had an extraordinary response to first-line treatment for metastatic HER2-positive breast cancer and remained on the same HER2-targeted therapy for 6 years.

Dana-Farber
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

HER2-Positive Breast Cancer With Metastatic Progression and Drug-Induced Lupus During T-DM1

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive, PR-negative, HER2-positive

Metastatic Site: bones, axillary lymph nodes, intra-abdominal lymph…

More than 5 years after her March 2018 diagnosis, she was living with metastatic breast cancer, but T-DM1 had been stopped after disease progression in 2023.

PubMed Central
OutcomeSetback / Progression